Stock Analysis

Formosan Union Chemical Third Quarter 2024 Earnings: EPS: NT$0.41 (vs NT$0.33 in 3Q 2023)

TWSE:1709
Source: Shutterstock

Formosan Union Chemical (TWSE:1709) Third Quarter 2024 Results

Key Financial Results

  • Revenue: NT$2.58b (up 11% from 3Q 2023).
  • Net income: NT$196.2m (up 26% from 3Q 2023).
  • Profit margin: 7.6% (up from 6.7% in 3Q 2023). The increase in margin was driven by higher revenue.
  • EPS: NT$0.41 (up from NT$0.33 in 3Q 2023).
earnings-and-revenue-history
TWSE:1709 Earnings and Revenue History November 18th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Formosan Union Chemical shares are down 4.8% from a week ago.

Risk Analysis

Before you take the next step you should know about the 1 warning sign for Formosan Union Chemical that we have uncovered.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About TWSE:1709

Formosan Union Chemical

Produces and sells chemical products in Taiwan, China, Guatamela, the Philippines, Vietnam, the Unites State, and internationally.

Flawless balance sheet with solid track record.

Community Narratives

AstraZeneca's Oncology and Obesity Innovations Will Drive Revenue Growth by 10%
Fair Value SEK 2.55k|37.875% undervalued
Unike
Unike
Community Contributor
Leading the Charge in SME SaaS Innovation
Fair Value SEK 100.02|24.815% undervalued
Investingwilly
Investingwilly
Community Contributor
Brookfield Corporation is a solid BUY for a long-term portfolio
Fair Value CA$82.23|4.8887% overvalued
Jonataninho
Jonataninho
Community Contributor